

21 January 2005

Level 14, Cigna House,
40 Mercer Street, PO Box 10-254
Wellington 6001, New Zealand
Phone 64 4 460 4990
Fax 64 4 460 4995
www.pharmac.govt.nz

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties*By facsimile (2 pages)***CONSULTATION ON AMENDED TERMS OF LISTING FOR CILAZAPRIL (INHIBACE), CILAZAPRIL WITH HYDROCHLOROTHIAZIDE (INHIBACE PLUS), AND CARVEDILOL (DILATREND) ON THE PHARMACEUTICAL SCHEDULE**

PHARMAC has reached provisional agreement with Roche Products (New Zealand) Limited which would amend the terms of listing for Inhibace, Inhibace Plus and Dilatrend in Section B of the Pharmaceutical Schedule (covering supply in the community). The agreement also includes the listing of Inhibace, Inhibace Plus and Dilatrend in Section H of the Pharmaceutical Schedule (covering supply to DHB hospitals).

Community Supply

The following is proposed in relation to community supply:

- the subsidy for Inhibace, Inhibace Plus and Dilatrend would be protected until 30 June 2007;
- Dilatrend would be subject to confidential rebate provisions;
- the price and subsidy for each pharmaceutical would be reduced from 1 March 2005 as shown in the table below:

Chemical – brand	Presentation	Units per pack	Current price and subsidy	Proposed price and subsidy from 1 March 2005
Cilazapril – Inhibace	Tab 0.5 mg	30	\$2.20	\$2.20
Cilazapril – Inhibace	Tab 2.5 mg	30	\$5.85	\$4.39
Cilazapril – Inhibace	Tab 5 mg	30	\$9.20	\$6.44
Cilazapril with hydrochlorothiazide – Inhibace Plus	Tab 5 mg with 12.5 mg	28	\$8.75	\$6.30
Carvedilol – Dilatrend	Tab 6.25 mg	30	\$28.00	\$21.00
Carvedilol – Dilatrend	Tab 12.5 mg	30	\$36.00	\$27.00
Carvedilol – Dilatrend	Tab 25 mg	30	\$45.00	\$33.75

Prices and subsidies are ex manufacturer, ex GST.

Hospital supply

Inhibace, Inhibace Plus and Dilatrend would be listed in Section H of the Pharmaceutical Schedule from 1 March 2005 at the same prices as shown in the table above.

If you wish to make comments for the PHARMAC Board (or Chief Executive under delegated authority) to consider when making its decision on whether to accept this proposal, please forward them to Hew Norris at PHARMAC by **4:00pm, Friday 4 February 2005**.

Yours sincerely

A handwritten signature in black ink, appearing to be 'H. Norris', followed by a long horizontal line extending to the right.

Hew Norris
Therapeutic Group Manager